ArcherDx has received breakthrough designation from the FDA for its companion diagnostic assay to analyze over 50 genes to identify alterations in somatic tumor DNA in plasma and in RNA or DNA taken from cancer tissue. Results generated by the sequencing-based test can be used to identify advanced non-small cell lung cancer patients who could benefit from a certain targeted therapy.
FDA grants breakthrough status to ArcherDx's companion diagnostic assay
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.